Clinical Presentation and Diagnostic Features
How Growth Hormone Causes Acromegaly
Growth hormone (GH) works directly on body tissues and indirectly through insulin-like growth factor-1 (IGF-1), which the liver produces. In healthy people, the hypothalamus tightly controls GH through regulatory hormones. Pituitary adenomas operate independently, bypassing these controls. Approximately 95% of cases result from pituitary tumors; the remaining 5% come from ectopic GH or GHRH secretion from neuroendocrine tumors.
IGF-1 mediates most GH effects, stimulating cell growth throughout the body. Children with open epiphyseal plates develop gigantism with increased height and proportionate skeletal growth. Adults with closed epiphyseal plates develop acromegaly with disproportionate enlargement of acral structures.
Clinical Features You Must Recognize
Acromegaly develops slowly over years, often causing delayed diagnosis. Early signs include increasing ring and shoe sizes, facial coarsening, and voice deepening.
Characteristic features include:
- Spade-like hands and feet with enlarged digits
- Prominent supraorbital ridges and prognathism (jaw protrusion)
- Macroglossia (enlarged tongue)
- Thickened lips, nose, and ears
- Thickened, oily skin with deepened folds
Systemic effects develop from prolonged hormone excess:
- Up to 60% develop sleep apnea from airway overgrowth
- Up to 50% develop diabetes or glucose intolerance
- Hypertension occurs in 30-50% of patients
- Patients report increased sweating and heat intolerance
Diagnostic Tests That Confirm Acromegaly
IGF-1 measurement is the primary screening test because it reflects 24-hour GH secretion without pulsatile fluctuations. Elevated IGF-1 for age and sex indicates possible acromegaly.
Confirmatory tests include:
- Fasting GH level greater than 1 ng/mL suggests pathology
- 75-gram oral glucose tolerance test is the gold standard. Normal people suppress GH below 1 ng/mL after glucose. Failure to suppress confirms acromegaly
- Pituitary MRI with contrast identifies adenomas, determines size, and evaluates optic chiasm compression
- Prolactin levels should be measured since many adenomas secrete both hormones
- Visual field testing if imaging suggests chiasm involvement
Clinical Presentation and Diagnostic Features
Cardiovascular Complications (The Primary Cause of Death)
Cardiovascular disease is the leading cause of mortality in acromegaly. Hypertension occurs in 30-50% of patients from sodium retention and vascular effects. Left ventricular hypertrophy develops from both hypertension and direct GH effects on the heart muscle.
Additional cardiac risks include:
- Diastolic dysfunction and reduced heart function
- Increased atherosclerosis risk (2-3 times higher than normal)
- Arrhythmias, particularly atrial fibrillation
- Progressive heart failure if untreated
Metabolic and Endocrine Complications
Diabetes mellitus develops in 20-25% of acromegalic patients, with another 25% experiencing glucose intolerance. These patients require intensive glycemic control. Secondary hypothyroidism occurs from mass effects on the pituitary. Hypogonadism results from suppressed gonadotropin levels.
Skeletal and Neurological Effects
Joint disease (arthropathy) affects knees, hips, and shoulders from cartilage overgrowth. Kyphosis and spinal stenosis develop from vertebral enlargement, risking myelopathy (spinal cord damage). Despite increased bone density, fracture risk paradoxically increases due to altered bone quality.
Mass effects from the pituitary adenoma cause:
- Visual field defects from optic chiasm compression
- Headaches from tumor mass
- Hypopituitarism requiring hormone replacement
- Potential memory impairment from prolonged hormone excess
Sleep Apnea and Malignancy Risk
Sleep apnea affects up to 60% of patients from upper airway obstruction and tongue enlargement. This significantly reduces quality of life and increases cardiovascular stress. Malignancy risk is elevated, particularly for colorectal cancer and thyroid tumors. Regular screening protocols are essential for early detection.
Complications and Systemic Effects
Biochemical Confirmation Tests
IGF-1 is your first-line screening test because it reflects integrated GH secretion over 24 hours. Unlike GH, which fluctuates throughout the day, IGF-1 remains stable and age-dependent. Consistently elevated fasting GH levels greater than 1-2 ng/mL suggest pathology.
The 75-gram oral glucose tolerance test is the gold standard. Normal people suppress GH below 1 ng/mL after glucose administration. Failure to suppress below this threshold confirms acromegaly.
Imaging and Visual Assessment
Pituitary MRI with contrast is essential to:
- Identify adenoma location and size
- Assess parasellar extension
- Evaluate optic chiasm compression
- Detect mass effects on surrounding structures
Visual field testing should be performed if imaging suggests chiasm involvement or if patients report visual symptoms.
Surgical Treatment: First-Line Option
Transsphenoidal pituitary surgery is first-line treatment for most patients when feasible. Success rates vary by tumor size:
- Microadenomas: 80-90% achieve normal GH and IGF-1
- Macroadenomas: 50-60% achieve control, especially with suprasellar extension
Surgery benefits include potential cure, rapid symptom relief, and avoiding long-term medication. Complications include temporary diabetes insipidus, cerebrospinal fluid leak, and hypopituitarism.
Medical Therapy Options
Medical therapy is used for patients unsuitable for surgery, incomplete surgical response, or perioperative management.
Available medications:
- Somatostatin analogs (octreotide, lanreotide) suppress GH and IGF-1
- Dopamine agonists provide modest GH reduction
- GH receptor antagonists (pegvisomant) block GH effects at peripheral tissues
Radiation Therapy
Radiation therapy is reserved for surgical failures or incomplete responses. Long-term hypopituitarism is a significant complication. Treatment goals include normalizing IGF-1 and reducing GH below 1 ng/mL to prevent disease progression.
Diagnostic Tests and Treatment Modalities
Post-Treatment Biochemical Monitoring
Comprehensive management extends beyond hormone normalization to address multisystem complications. Post-treatment monitoring requires periodic biochemical assessment to confirm adequate suppression and detect recurrence.
Recommended monitoring schedule:
- IGF-1 measurement every 6-12 months after treatment stabilization
- Fasting GH levels to assess long-term control
- More frequent testing during initial treatment phase
Cardiovascular and Sleep Evaluation
Sleep studies are critical given that up to 60% of patients develop sleep apnea. Continuous positive airway pressure (CPAP) therapy is often required. Baseline cardiovascular evaluation includes:
- Blood pressure monitoring
- Electrocardiography
- Echocardiography
- Repeat testing if clinical changes suggest cardiac involvement
- Antihypertensive and lipid-lowering medications are frequently necessary
Metabolic and Endocrine Assessment
Glucose monitoring is essential given diabetes risk. Tests include:
- Fasting glucose
- Hemoglobin A1c
- Oral glucose tolerance testing
- Aggressive glycemic control minimizes complications
Thyroid and adrenal function tests identify hormone deficiencies from mass effects. Bone mineral density screening using DXA is recommended, though treatment decisions are complex.
Malignancy and Vision Screening
Colonoscopy is recommended for colorectal cancer screening due to increased malignancy risk. Visual field testing should be repeated if optical symptoms develop or imaging shows chiasm involvement. Quality of life assessments should guide treatment intensity, as some patients achieve biochemical control with persistent symptoms.
Long-Term Follow-Up
Regular follow-up with endocrinologists experienced in acromegaly management optimizes outcomes. Patient education regarding disease progression, medication adherence, and monitoring importance is critical for success. Multidisciplinary care involving cardiology, sleep medicine, and neurosurgery may be necessary for complex cases.
Clinical Management and Monitoring Strategies
Creating an Effective Study Plan
Flashcards excel for acromegaly study because the condition involves numerous clinical features, diagnostic criteria, complications, and management options. Creating flashcards forces active learning as you synthesize information into questions and answers, promoting deeper understanding.
Organization Strategies for Maximum Retention
Organize your flashcard deck by category:
- Pathophysiology: GH mechanisms, pituitary adenomas, IGF-1 effects
- Clinical Features: Acral signs, systemic manifestations, differential diagnosis
- Diagnostic Tests: IGF-1, GH suppression testing, MRI findings
- Complications: Cardiovascular, metabolic, skeletal, neurological effects
- Treatment Options: Surgical outcomes, medical therapies, monitoring protocols
Spaced repetition through flashcard review strengthens long-term memory retention better than passive reading. Visual memory can be enhanced by including clinical images of acral features and diagnostic imaging on cards.
Advanced Study Techniques
Test yourself on:
- Diagnostic test interpretation and normal values
- Differential diagnosis from other conditions
- Treatment selection based on tumor size and patient factors
- Complication management and monitoring schedules
Digital flashcard apps enable efficient study during limited time periods, essential for busy students. Focus extra cards on challenging areas like distinguishing acromegaly from gigantism or comparing treatment options.